Achieve Life Sciences Inc. (ACHV)
Achieve Life Sciences: A Binary Bet With Cytisinicline And A Potential 2026 Launch
Achieve Life Sciences is a single-asset microcap centered on cytisinicline, with an accepted NDA and a June 20, 2026, PDUFA. Cytisinicline's α4β2 partial agonism aims to reduce cravings and blunt nicotine reward. In fact, the most promising aspect of cytisinicline was that its Phase 3 ORCA trials showed strong quit-rate deltas versus placebo.
Achieve Life Sciences: Could Be The Best 'Tobacco' Stock For 2026 - Strong Buy
Achieve Life Sciences is a late-stage Pharma company awaiting FDA approval for Cytisinicline, a novel (though proven) smoking cessation therapy, with a decision expected in June. Cytisinicline demonstrates superior efficacy and safety versus current treatments, with strong precedent in Europe and a large, underserved U.S. market. ACHV's market cap (~$250M) is a fraction of its potential, with peak sales for smoking and vaping cessation possibly reaching $2–3 billion.
Achieve Life Sciences, Inc. (ACHV) Q3 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. ( ACHV ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Nicole Jones Richard A. Stewart - CEO & Executive Director Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Jerry Wan - VP of Finance & Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Brandon Folkes - H.C.
Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q2 2025 Earnings Call August 7, 2025 8:30 AM ET Company Participants Cindy Jacobs - Former President & Chief Medical Officer Jaime Xinos - Chief Commercial Officer Mark K. Oki - Chief Financial Officer Nicole Jones - Corporate Participant Richard A.
Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation
ACHV's cytisinicline shows best-in-class efficacy and safety for smoking cessation, supported by strong clinical data and recent NDA submission. The target market is large, with millions seeking smoking cessation annually. Recent financing extends ACHV's cash runway through FDA approval, but further capital will be needed for commercialization.
Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk
Achieve Life Sciences (ACHV) is positioned for growth with its lead smoking cessation therapy, cytisinicline, advancing through late-stage clinical trials. The company addresses a significant unmet need in tobacco addiction, with cytisinicline showing promising efficacy and safety data compared to existing therapies. While FDA approval may be difficult, the low valuation and high potential peak sales provide a decent risk/reward profile.
Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Nicole Jones - Investor Relations Rick Stewart - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Mark Oki - Chief Financial Officer Jaime Xinos - Chief Commercial Officer Conference Call Participants Gary Nachman - Raymond James Justin Walsh - Jones Trading John Vandermosten - Zacks Investment Research Operator Greetings. Welcome to Achieve Life Sciences First Quarter 2025 Earnings Conference Call and Webcast.
Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Nicole Jones - IR Richard Stewart - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jaime Xinos - Chief Commercial Officer Mark Oki - Chief Financial Officer Conference Call Participants Gary Nachman - Raymond James Thomas Flaten - Lake Street Capital Markets Francois Brisebois - Oppenheimer and Company Justin Walsh - Jones Trading Brandon Folkes - Rodman & Renshaw John Vandermosten - Zacks SCR Boris Tolkachev - Freedom Broker Operator Greetings, and welcome to the Achieve Life Sciences Fourth Quarter and Year-End 2024 Earnings Call and Webcast. At this time all participants are in a listen-only mode.
Achieve Life Sciences, Inc. (ACHV) Q3 2024 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Nicole Jones - IR Richard Stewart - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Jerry Wan - Principal Accounting Officer Jaime Xinos - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Justin Walsh - JonesTrading John Vandermosten - Zacks Small-Cap Research Gary Nachman - Raymond James Boris Tolkachev - Freedom Broker Operator Greetings, and welcome to the Achieve Life Sciences Third Quarter 2024 Earnings Conference Call and Webcast. [Operator Instructions] And as a reminder, this conference is being recorded.
Achieve Life Sciences, Inc. (ACHV) Q2 2024 Earnings Call Transcript
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Nicole Jones - IR John Bencich - CEO Cindy Jacobs - President and Chief Medical Officer Jerry Wan - Principal Accounting Officer Conference Call Participants Thomas Flaten - Lake Street Capital Justin Walsh - JonesTrading John Vandermosten - Zacks Ilya Zubkov - Freedom Broker Thomas Flaten - Lake Street Capital Operator Greetings, and welcome to the Achieve Life Sciences Second Quarter 2024 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
